

Supplemental Table S3. DDR-related proteins are prognostic for overall survival in patients receiving venetoclax + HMA therapy (VH).

Patients receiving venetoclax plus hypomethylating agent (HMA) therapy (VH)					
Protein Name	Overall survival stratifications				
	Median Split	Terciles	Quartiles	Quintiles	Sextiles
SSBP2	0.026	0.18	0.16	0.074	0.19
MSH6	0.62	0.2	0.022	0.45	0.2
TP53BP1	0.038	0.38	0.18	0.4	0.29
RAD51	0.022	0.24	0.077	0.21	0.2
CHEK2	0.0013	0.058	0.011	0.014	0.026
SIRT6	0.021	0.23	0.15	0.076	0.27
PDCD1	0.033	0.082	0.2	0.17	0.076
TP53	0.81	0.2	0.79	0.78	0.029
CDK1	0.43	0.13	0.038	0.18	0.38
CDK1_2_3.pT14	0.0098	0.0078	0.049	0.02	0.055
CDK9	0.041	0.0052	0.14	0.071	0.038
CDKN1B	0.0001	0.0001	0.0001	0.0001	0.00016
CDKN1B.pS10	0.0005	0.00016	0.00023	0.00044	0.0001
CDKN1B.pT198	0.0038	0.03	0.028	0.12	0.085
RPA32.pS4_8	0.026	0.092	0.12	0.14	0.25